BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30010036)

  • 1. 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer.
    Zhang J; Han X; Gao C; Xing Y; Qi Z; Liu R; Wang Y; Zhang X; Yang YG; Li X; Sun B; Tian X
    Genomics Proteomics Bioinformatics; 2018 Jun; 16(3):187-199. PubMed ID: 30010036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers.
    Li W; Zhang X; Lu X; You L; Song Y; Luo Z; Zhang J; Nie J; Zheng W; Xu D; Wang Y; Dong Y; Yu S; Hong J; Shi J; Hao H; Luo F; Hua L; Wang P; Qian X; Yuan F; Wei L; Cui M; Zhang T; Liao Q; Dai M; Liu Z; Chen G; Meckel K; Adhikari S; Jia G; Bissonnette MB; Zhang X; Zhao Y; Zhang W; He C; Liu J
    Cell Res; 2017 Oct; 27(10):1243-1257. PubMed ID: 28925386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages.
    Song CX; Yin S; Ma L; Wheeler A; Chen Y; Zhang Y; Liu B; Xiong J; Zhang W; Hu J; Zhou Z; Dong B; Tian Z; Jeffrey SS; Chua MS; So S; Li W; Wei Y; Diao J; Xie D; Quake SR
    Cell Res; 2017 Oct; 27(10):1231-1242. PubMed ID: 28820176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
    Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
    Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
    J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer.
    Hu X; Luo K; Shi H; Yan X; Huang R; Zhao B; Zhang J; Xie D; Zhang W
    Clin Epigenetics; 2022 Jan; 14(1):15. PubMed ID: 35073982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research progress of circulating tumor DNA methylation in non-small cell lung cancer].
    Yang Lan L; Chen Bojiang BJ; Li Lei L
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Dec; 41(12):967-970. PubMed ID: 30522195
    [No Abstract]   [Full Text] [Related]  

  • 9. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
    Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
    Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
    Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
    Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
    [No Abstract]   [Full Text] [Related]  

  • 12. Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules.
    Chen C; Huang X; Yin W; Peng M; Wu F; Wu X; Tang J; Chen M; Wang X; Hulbert A; Brock MV; Liu W; Herman JG; Yu F
    Clin Epigenetics; 2020 Mar; 12(1):39. PubMed ID: 32138766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
    Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
    Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma.
    Xiao Z; Wu W; Wu C; Li M; Sun F; Zheng L; Liu G; Li X; Yun Z; Tang J; Yu Y; Luo S; Sun W; Feng X; Cheng Q; Tao X; Wu S; Tao J
    Mol Oncol; 2021 Jan; 15(1):138-150. PubMed ID: 33107199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.
    Chen L; Shen Q; Xu S; Yu H; Pei S; Zhang Y; He X; Wang Q; Li D
    J Alzheimers Dis; 2022; 85(2):573-585. PubMed ID: 34864677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Highly Sensitive and Specific Non-Invasive Test through Genome-Wide 5-Hydroxymethylation Mapping for Early Detection of Lung Cancer.
    Ren Y; Zhang Z; She Y; He Y; Li D; Shi Y; He C; Yang Y; Zhang W; Chen C
    Small Methods; 2024 Mar; 8(3):e2300747. PubMed ID: 37990399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
    Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
    Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.